CUREVAC NV (CVAC)
NL0015436031 - Common Stock
We assign a fundamental rating of 2 out of 10 to CVAC. CVAC was compared to 588 industry peers in the Biotechnology industry. CVAC has a bad profitability rating. Also its financial health evaluation is rather negative. CVAC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CVAC had negative earnings in the past year.
CVAC had a negative operating cash flow in the past year.
In the past 5 years CVAC always reported negative net income.
In the past 5 years CVAC reported 4 times negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -33.01%, CVAC is doing good in the industry, outperforming 68.94% of the companies in the same industry.
CVAC's Return On Equity of -50.33% is fine compared to the rest of the industry. CVAC outperforms 67.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.01% | ||
| ROE | -50.33% | ||
| ROIC | N/A |
ROA(3y)-32.5%
ROA(5y)-36.5%
ROE(3y)-52.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CVAC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CVAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CVAC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CVAC has been increased compared to 5 years ago.
The debt/assets ratio for CVAC is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.66, we must say that CVAC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.66, CVAC is in the better half of the industry, outperforming 68.26% of the companies in the same industry.
A Debt/Equity ratio of 0.07 indicates that CVAC is not too dependend on debt financing.
CVAC's Debt to Equity ratio of 0.07 is on the low side compared to the rest of the industry. CVAC is outperformed by 62.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.66 |
ROIC/WACCN/A
WACC6.84%
2.3 Liquidity
CVAC has a Current Ratio of 2.57. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
CVAC's Current ratio of 2.57 is on the low side compared to the rest of the industry. CVAC is outperformed by 72.01% of its industry peers.
CVAC has a Quick Ratio of 2.43. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.43, CVAC is doing worse than 72.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.57 | ||
| Quick Ratio | 2.43 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.95% over the past year.
CVAC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -20.26%.
Measured over the past years, CVAC shows a very strong growth in Revenue. The Revenue has been growing by 33.04% on average per year.
EPS 1Y (TTM)4.95%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q35.24%
Revenue 1Y (TTM)-20.26%
Revenue growth 3Y3.21%
Revenue growth 5Y33.04%
Revenue growth Q2Q93.05%
3.2 Future
The Earnings Per Share is expected to grow by 7.63% on average over the next years.
Based on estimates for the next years, CVAC will show a very strong growth in Revenue. The Revenue will grow by 39.15% on average per year.
EPS Next Y5.1%
EPS Next 2Y11.65%
EPS Next 3Y9.88%
EPS Next 5Y7.63%
Revenue Next Year27.16%
Revenue Next 2Y27.47%
Revenue Next 3Y68.37%
Revenue Next 5Y39.15%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CVAC. In the last year negative earnings were reported.
Also next year CVAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.65%
EPS Next 3Y9.88%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CUREVAC NV
NASDAQ:CVAC (5/3/2024, 7:00:01 PM)
After market: 3.15 +0.02 (+0.64%)3.13
+0.36 (+13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap702.09M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.01% | ||
| ROE | -50.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.57 | ||
| Quick Ratio | 2.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)4.95%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y5.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-20.26%
Revenue growth 3Y3.21%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y